Duodenal adenocarcinoma with neuroendocrine features in a patient with acromegaly and thyroid papillary adenocarcinoma: a unique combination of endocrine neoplasia

Kato, Kenichiro; Takeshita, Yumie; Makino, Hírofumi; Ishikura, Kazuhide; Kakinoki, Kaheita; Kitamura, Seiichiro; Kaneko, Shuichi; Takamura, Toshinari

doi:10.1507/endocrj.ej11-0324

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, Kato et al [4] reported one case of duodenal adenocarcinoma with NEF at the descending part in a 67-year-old woman. However, it was accompanied by acromegaly and other types of tumors, namely GHproducing pituitary adenoma and thyroid papillary adenocarcinoma with familial clustering.…”

Section: Discussionmentioning

confidence: 99%

“…One case of duodenal adenocarcinoma with NEF combined with liver metastasis survived for more than 24 mo without progression of the primary and metastatic lesions. It is plausible that duodenal adenocarcinoma with NEF is predominantly a neuroendocrine tumor of low malignancy potential, rather than a common adenocarcinoma [4] . Malignant NET, such as type 3 gastric NETs which are considered to be aggressive and often with metastasis, can also be treated successfully by endoscopic treatment, including EMR [10] .…”

Section: Discussionmentioning

confidence: 99%

“…Histologically, 40% of small bowel cancer are adenocarcinoma and another 40% are neuroendocrine tumors. Recently, a rare case of duodenal adenocarcinoma with neuroendocrine features (NEF) was reported that was neither a conventional neuroendocrine tumor nor a typical duodenal adenocarcinoma [4] . It remains unclear whether duodenal adenocarcinoma with NEF should be treated as adenocarcinoma or neuroendocrine tumors or both.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Endoscopic mucosal resection of duodenal bulb adenocarcinoma with neuroendocrine features: An extremely rare case report

Wen¹

2015

WJG

View full text Add to dashboard Cite

Duodenal adenocarcinoma, especially duodenal bulb with neuroendocrine features (NEF), is extremely rare. Here, we report one such case of duodenal bulb adenocarcinoma with neuroendocrine features. A 63-year-old Han Chinese woman was admitted to our department with the diagnosis of a duodenal bulb polyp and underwent an endoscopic mucosal resection. The pathological findings confirmed it as duodenal bulb adenocarcinoma with NEF. The patient remains curative after one and half a years of follow-up. Duodenal adenocarcinoma with NEF might be a low malignant neuroendocrine tumor rather than a conventional adenocarcinoma. Endoscopic treatment, including endoscopic mucosal resection, might be an ideal option for the adenocarcinomas with NEF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endoscopic mucosal resection of duodenal bulb adenocarcinoma with neuroendocrine features: An extremely rare case report

Wen¹

2015

WJG

View full text Add to dashboard Cite

show abstract

“…The use of octreotide marked with a radioactive element to treat neuroendocrine tumors is currently being investigated [23]. Several studies have found that octreotide could be used to treat neuroendocrine tumors [24] and duodenal adenocarcinoma [25], and it may reduce liver metastasis. Octreotide may induce morphological changes and mitochondrial vacuolization that trigger apoptosis in liver cancer cells [26].…”

Section: Discussionmentioning

confidence: 99%

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

Huang

Liu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Hepatocellular carcinoma (HCC) is a major threat to human health. The condition carries a high risk of death; 45% of new cases occur in China. Surgical resection is the first choice for treatment of HCC, but 30.9% of patients experience recurrence within 6 months after the operation. To improve patient survival, we must determine how to reduce the probability of recurrence and metastasis and elucidate the underlying mechanism of disease. We therefore studied the effect of somatostatin octapeptide (octreotide) on the invasion and metastasis of HCC. Methods: The migration and invasion cytological tests were used to detect the effect of octreotide on liver cancer cells (SK-Hep-1 and HepG2). PEBP1 RNAi was used to knockdown expression. Invasion and metastasis were measured with transwell migration and wound-healing assays. Western blotting was used to detect changes in levels of PEBP1 and invasion pathway proteins after octreotide treatment. The effect of octreotide was studied in vivo by establishing a pulmonary metastasis model using SK-Hep-1 cells in nude mice. In-vivo bioluminescence imaging and hematoxylin and eosin staining of lung tissue were used to verify the results. Results: Increasing concentrations of octreotide were progressively more effective in halting the invasion and metastasis of liver cancer cells. Octreotide may upregulate PEBP1, TIMP-2, and E-cadherin while downregulating MMP-2 and Twist to inhibit cell invasion and metastasis. And downregulation of PEBP1 would also change the expression of MMP-2, TIMP-2 and Twist. The in-vivo experiments showed no cancer cell metastasis in 4 of the 6 mice in the octreotide-treatment group, while all of the mice in the control group displayed pulmonary metastasis of human HCC cells. And the survival period of the mice in the octreotide-treatment group was significantly prolonged. Conclusions: Octreotide may weaken invasion and metastasis through the upregulation of PEBP1. Octreotide may reduce the risk of recurrence and metastasis after surgery for liver cancer.

show abstract

“…Previously, Kato et al[ 6 ] reported a case of duodenal adenocarcinoma with neuroendocrine features in a 67-year-old woman with acromegaly and thyroid papillary adenocarcinoma. Wen et al[ 7 ] reported a case of duodenal bulb adenocarcinoma with neuroendocrine features in a 63-year-old woman, which was treated by endoscopic mucosal resection.…”

Section: Discussionmentioning

confidence: 99%

Case of a tumor comprising gastric cancer and duodenal neuroendocrine tumor

Kaneko¹,

Miyake²,

Ishii³

et al. 2016

WJG

View full text Add to dashboard Cite

The present report describes a rare case of a tumor composed of early gastric cancer and a duodenal neuroendocrine tumor (NET). A 78-year-old woman underwent esophagogastroduodenoscopy at a local institution for screening of the upper gastrointestinal tract which revealed a protruded tumor through the pyloric ring from the pyloric antrum. The tumor was too large to treat at the facility; consequently, she was referred to our hospital for further management. Esophagogastroduodenoscopy with tumor biopsy of the lesion revealed the diagnosis of early gastric cancer. Endoscopic submucosal dissection was performed with sufficient free margins in both vertical and horizontal directions. Histopathological findings showed NET confined to the submucosal layer and covered by well-differentiated adenocarcinoma. Immunohistochemical stainings showed that the two lesions existed continuously. While the possibility of a collision cancer was considered, it was suggested that the two lesions existed continuously. Finally, the tumor was diagnosed as gastric cancer composed of duodenal NET G1, with a lymphatic invasion of NET component.

show abstract

Duodenal adenocarcinoma with neuroendocrine features in a patient with acromegaly and thyroid papillary adenocarcinoma: a unique combination of endocrine neoplasia

Cited by 5 publications

References 30 publications

Endoscopic mucosal resection of duodenal bulb adenocarcinoma with neuroendocrine features: An extremely rare case report

Endoscopic mucosal resection of duodenal bulb adenocarcinoma with neuroendocrine features: An extremely rare case report

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

Case of a tumor comprising gastric cancer and duodenal neuroendocrine tumor

Contact Info

Product

Resources

About